Neonatal drug withdrawal.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22291123.
- Also identified by DOI 10.1542/peds.2011-3212.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Maternal use of certain drugs during pregnancy can result in transient neonatal signs consistent with withdrawal or acute toxicity or cause sustained signs consistent with a lasting drug effect. In addition, hospitalized infants who are treated with opioids or benzodiazepines to provide analgesia or sedation may be at risk for manifesting signs of withdrawal. This statement updates information about the clinical presentation of infants exposed to intrauterine drugs and the therapeutic options for treatment of withdrawal and is expanded to include evidence-based approaches to the management of the hospitalized infant who requires weaning from analgesics or sedatives.
Medical subject headings
- Analgesics, Opioid
- Benzodiazepines
- Evidence-Based Medicine
- Hypnotics and Sedatives
- Illicit Drugs
- Neonatal Abstinence Syndrome